ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 837.3 USD | +0.66% |
|
+2.73% | +43.64% |
| Jun. 06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| Jun. 06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.29% | 36 M€ | +2.50% | - | |
| 0.27% | 1 M€ | -.--% | - | |
| 0.24% | 12 M€ | +18.05% | - | |
| 0.23% | 17 M€ | +4.86% | - | |
| 0.22% | 105 M€ | +4.21% | - | |
| 0.21% | 7 M€ | +5.33% | - | |
| 0.21% | 32 M€ | +0.47% | - | |
| 0.21% | 17 M€ | +5.32% | - | |
| 0.20% | 253 M€ | +7.04% | ||
| 0.19% | 17 M€ | +3.59% | - | |
| 0.18% | 20 M€ | +0.65% | - | |
| 0.17% | 32 M€ | +1.00% | - | |
| 0.15% | 2 M€ | +6.77% | - | |
| 0.15% | 234 M€ | +11.44% | - | |
| 0.11% | 2 M€ | +3.16% | - | |
| 0.11% | 23 M€ | +16.95% | - | |
| 0.11% | 54 M€ | +1.52% | - | |
| 0.10% | 756 M€ | +1.50% | - | |
| 0.09% | 8 M€ | +1.40% | - | |
| 0.08% | 6 M€ | -4.26% | - | |
| 0.08% | 3 M€ | +7.10% | - | |
| 0.02% | 104 M€ | +10.63% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
853.8
USD
Spread / Average Target
+1.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B | |
| +1.39% | 124B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
